New treatments for peanut allergies sound promising, but questions remain

Washington Post, January 6, 2019
by Shefali Luthra, quoting W. Nicholson Price (Academic Fellow Alumnus)

From the article: "What’s new is the addition of labor, standardization and federal oversight — which companies then say demonstrates increased value. It highlights a pattern I’ve noticed from…

Read More

House Democrats make Day 1 largely about health care

Politico Pulse, January 4, 2019
by Dan Diamond, featuring work by Rachel Sachs

From the article: "In Health Affairs, Rachel Sachs reviews the looming prescription drug policy issues." Read more here!

Read More

Drug makers resist pressure from Washington on prices

CNN, January 3, 2019
by Tami Lubhy, quoting Rachel Sachs

From the article: "Much of what the Department of Health & Human Services has done so far consists of putting forward proposals, largely involving what Medicare will pay for medications. One of the more significant…

Read More

Carpus Dicit: Special Report

Harvard Medicine, Winter 2019
by Monique Brouillette, quoting I. Glenn Cohen (Faculty Director)

From the article: "For I. Glenn Cohen, the James A. Attwood and Leslie Williams Professor of Law at Harvard Law School, the degree of worry over our data should vary depending on which data are being considered. When consumers are worried about losing…

Read More

Hatch’s Swan Song: A Bill to Block Generic Companies’ IPR Filings

RAPS Regulatory Focus, December 14, 2018
by Zachary Brennan, quoting Jonathan Darrow (Student Fellow Alumnus)

From the article:  Retiring Sen. Orrin Hatch (R-UT) and two Republican colleagues in the House and Senate proposed a bill earlier this week to prevent generic drug applicants from taking advantage of the inter partes review (IPR) created under…

Read More

A groundbreaking antitrust lawsuit is ensnaring the generic drug industry

Vox, December 10, 2018
By Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "The exact damages are difficult to know but likely total in the billions of dollars if the allegations are true. These artificially high prices led to health plans and government programs paying more money. Patients who don’t…

Read More

Democrats are suddenly eyeing a valuable pharma asset: its patents

Stat, December 7, 2018
by Lev Facher, quoting Rachel Sachs (Academic Fellow Alumna)

From this article: "Democrats, newly empowered in D.C. and on the hunt for bigger and bolder ways to lower drug prices, are suddenly taking aim at a far more central part of pharma’s monopoly power: the patents the industry holds on its drugs. …

Read More

An Inside Look at Apple’s Biggest Step Yet in Health Care

Time, December 6, 2018
by Alex Fitzpatrick, quoting W. Nicholson Price (Academic Fellow Alumnus)

From the article: "In the long run, however, it’s privacy concerns that have the biggest potential to hamper tech companies’ health dreams. News of data breaches that expose consumers’ personal information have become practically…

Read More

#CRISPRbabies: What’s the future of gene editing?

Al Jazeera, December 5, 2018
The Stream, interviewing I. Glenn Cohen (Faculty Director)

From the episode:  "A Chinese scientist claims to have created the world's first genetically edited babies: Twin girls who are resistant to HIV. The results of He Jiankui’s experiment have yet to be independently verified,…

Read More

Are IVF embryos persons? A mum and dad who lost theirs say they are

BioEdge, December 1, 2018
By Michael Cook, quoting I. Glenn Cohen (Faculty Director)

From the article: "The 'chain of profound implications for other families' dismays three bioethicists and lawyers writing in Annals of Internal Medicine, Eli Adashi, of Brown University; I. Glenn Cohen, of Harvard; and Dov Fox, of…

Read More

Genetically Modified People Are Walking Among Us

New York Times, December 1, 2018
By Carl Zimmer, interviewing I. Glenn Cohen (Faculty Director)

From the article: "I got in touch with Glenn Cohen, a professor at Harvard Law School who studies reproductive technologies, to ask him to guess what happens next. His forecast sounded like a repeat of the mitochondrial replacement story.

Read More

Something Happened to U.S. Drug Costs in the 1990s

New York Times, November 12, 2018
Austin Frakt quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: “Other countries decline to pay for a drug when the price is too high,” said Rachel Sachs, who studies drug pricing and regulation as an associate professor of law at Washington University in St. Louis. “The United…

Read More

Regulatory Collaboration Is Key to Public Health Success

The Regulatory Review, October 26, 2018
Benjamin Barsky, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: "Federal policymakers have recently made a push to address excessive drug price increases and slow medicine development as part of their health care agenda. But the latest health…

Read More

Experts caution on implications of ‘lost embryos’ lawsuit

BioNews, November 26, 2018
By Lone Hørlyck, quoting I. Glenn Cohen (Faculty Director)

From the article: "In addition to the potential implications for IVF treatments, considering embryos as persons could be used to argue against abortion rights and embryonic stem cell research. Professor Adashi, along…

Read More

Can OSHA Regulation Rescue NFL Players?

Regulatory Review, November 21, 2018
by Grace Gale, quoting I. Glenn Cohen (Faculty Director)

From the article: "According to a recent article, the answer is 'yes.' The Occupational Safety and Health Administration (OSHA) should issue rules to make football safer, say the article’s authors.

Read More

Slow thinking and machine learning in medicine, November 9, 2018
Drea Burbank, Ayo Roberts, and Chandi Broadbent, quoting I. Glenn Cohen (Faculty Director)

From the article:  Recently, several high-profile institutions have called attention to the issue of inclusion and equity when artificial intelligence (AI) algorithms are applied in medicine. Leaders from the law, medicine,…

Read More

Trump prescription medication plan drawing skepticism

Boston Herald, November 3, 2018
Alexi Cohan, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Part of the proposal includes adopting an international pricing index for reimbursement that is based off the cost of certain drugs in other countries. This would lower the cost here in the United States, which can drop out-of-pocket expenses…

Read More

Colorado Supreme Court Quotes I. Glenn Cohen: "In re Marriage of Rooks— Divorce—Assisted Reproduction—Embryos"

Justice William W. Hood III, quoting I. Glenn Cohen (Faculty Director)

The Colorado Supreme Court in a dissent by Justice Hood, joined Coats and Samour, quotes I. Glenn Cohen.  From the dissent:  For the non-consenting donor, there are several harms that may be inflicted, each of which derives “from…

Read More

Colorado Supreme Court creates rules for divorced couples divided over fate of their frozen embryos: Case could potentially be considered by U.S. Supreme Court

The Denver Post, October 29, 2018
Elise Schmelzer, quoting I. Glenn Cohen (Faculty Director)

From the article:  While other states have considered similar cases, the guidelines issued by the Colorado court are some of the most specific created by any state on the issue, said Glenn Cohen, a Harvard University law professor who specializes…

Read More

Trump leans into midterms with a pitch to un-rig Medicare drug prices

CNN Politics, October 25, 2018
Tami Luhby and Lauren Fox, quoting Rachel Sachs (Academic Fellow Alumna)

From the article:  While Trump officials could use an Obamacare-created innovation center to pilot new payment proposals, it would have to take a hard stance on prices. "We don't negotiate because we don't use the threat of walking…

Read More